6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04232969
(ClinicalTrials.gov)
January 20, 202010/1/2020Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseA Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseParkinson's DiseaseDrug: Exenatide extended release 2mg (Bydureon)University College, LondonNULLRecruiting25 Years80 YearsAll200Phase 3United Kingdom
2EUCTR2019-000732-26-SE
(EUCTR)
23/10/201907/05/2019Exenatide Treatment in Parkinson's DiseaseEffect of Exenatide on disease progression in early Parkinson's disease. Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Bydureon 2 mg powder and solvent for prolonged-release suspension
Product Name: BYDUREON
INN or Proposed INN: EXENATIDE
Stockholm Health Care ServicesNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2Sweden
3EUCTR2013-003363-64-GB
(EUCTR)
03/04/201411/03/2014Trial of Exenatide for Parkinson's diseaseA randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease. - Exenatide-PD Parkinson's Disease
MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Bydureon
Product Name: Exenatide
INN or Proposed INN: exenatide
University College LondonNULLNot RecruitingFemale: yes
Male: yes
60Phase 2United Kingdom